Tonix Pharmaceuticals Holding Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SALE AND PURCHASE OF COMMON STOCK (Details Narrative)

SALE AND PURCHASE OF COMMON STOCK (Details Narrative) - USD ($)													1 Months Ended	3 Months Ended					9 Months Ended
	Jul. 31, 2024	Jul. 09, 2024	Jun. 27, 2024	Jun. 12, 2024	Apr. 02, 2024	Mar. 28, 2024	Dec. 20, 2023	Oct. 03, 2023	Aug. 01, 2023	Jul. 27, 2023	Aug. 16, 2022	Apr. 08, 2020	Nov. 12, 2024	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	May 22, 2024	Jan. 25, 2024	Dec. 31, 2023
Stock offering expenses																			$ 3,942,000	$ 863,000
Common stock, authorized							160,000,000							1,000,000,000					1,000,000,000			1,000,000,000	160,000,000
Value of shares issued														$ 3,484,000	$ 10,730,000	$ 6,274,000	$ 1,029,000	$ 1,995,000
Repurchase of common stock																				13,965,000
2024 Share Repurchase Program [Member]
Share repurchase authorized amount																$ 10,000,000				$ 10,000,000
2022 Share Repurchase Program [Member]
Share repurchase authorized amount																		$ 12,500,000
Shares repurchased																		78,502
Repurchase of common stock																		$ 12,500,000
2022 Share Repurchase Program [Member] \| Minimum [Member]
Price per share																		$ 88.00
2022 Share Repurchase Program [Member] \| Maximum [Member]
Price per share																		$ 275.52
2023 Share Repurchase Program [Member]
Share repurchase authorized amount																		$ 12,500,000
Shares repurchased																		5,000
Price per share																		$ 227.84
Repurchase of common stock																		$ 1,100,000
Pre-Funded Warrants [Member]
Number of warrants exercised																			11,315,090
Common Warrants [Member]
Number of shares for common warrants					217,188
Exercise price					$ 10.56																$ 10.56
Termination date					Apr. 01, 2029
Common Warrants Series A [Member]
Number of shares for common warrants					278,125
Termination date					Apr. 01, 2029
Common Warrants Series B [Member]
Number of shares for common warrants					278,125
Termination date					Apr. 01, 2025
Common Warrants Series C [Member]
Number of shares for common warrants					1,088,248
Termination date					Apr. 01, 2026
Period of trading days after FDA acceptance of NDA for warrant expiration					10 days
Common Warrants Series D [Member]
Number of shares for common warrants					1,088,248
Termination date					Apr. 01, 2029
Purchase Agreement [Member]
Number of shares issued			2,833,900	1,199,448			791,977
Price per share			$ 0.57	$ 1.065
Offering expenses		$ 500,000
Placement Agent Fees		300,000
Net proceeds		$ 3,500,000	$ 3,500,000	$ 3,500,000
Stock offering expenses			500,000	500,000
Placement agent fees			$ 300,000	$ 300,000
Proceeds from equity offerings							$ 30,000,000
Purchase Agreement [Member] \| Pre-Funded Warrants [Member]
Number of shares for common warrants		3,703,140	4,228,158	2,568,110			897,213
Price per share		$ 0.5699	$ 0.5699	$ 1.064			$ 17.7568
Exercise price							$ 0.0001
Number of warrants exercised							203,407
Purchase Agreement [Member] \| Common Warrants [Member]
Price per share							$ 17.76
Purchase Agreement [Member] \| Common Warrants Series C [Member]
Number of shares for common warrants							2,533,784
Exercise price							$ 17.76
Warrants term							2 years
Period of trading days after FDA acceptance of NDA for warrant expiration							10 days
Proceeds from equity offerings							$ 14,400,000
Common stock, authorized for warrant exercise																							1,000,000,000
Period of trading days after approval date to become exercisable							10 days
Purchase Agreement [Member] \| Common Warrants Series D [Member]
Number of shares for common warrants							2,533,784
Exercise price							$ 27.20
Warrants term							5 years
Purchase Agreement [Member] \| Equity Classified Common Warrants D [Member]
Number of shares for common warrants							1,591,665
Purchase Agreement [Member] \| Liability Classified Common Warrants C and D [Member]
Number of shares for common warrants							942,120
Stock offering expenses							$ 900,000
Purchase Agreement [Member] \| Liability Classified Common Warrants D [Member]
Proceeds from equity offerings							8,100,000
Sales Agreement [Member]
Number of shares issued						336,459		126,563		79,062
Price per share						$ 9.60
Net proceeds						$ 3,900,000		$ 4,000,000	$ 6,300,000
Stock offering expenses						500,000	2,300,000	500,000	700,000
Placement agent fees						$ 300,000		$ 300,000	$ 500,000
Offset to proceeds from issuance of warrants																			$ 3,000,000
Sales Agreement [Member] \| Subsequent Event [Member]
Number of shares issued													31,300,000
Net proceeds													$ 5,100,000
Sales Agreement [Member] \| Alliance Global Partners [Member]
Number of shares issued														134,500,000		0				29,855
Net proceeds														$ 41,800,000		$ 0				$ 3,000,000
Offering price per agreement	$ 150,000,000											$ 320,000,000
Commission to agent	3.00%											3.00%
Sales Agreement [Member] \| Pre-Funded Warrants [Member]
Number of shares for common warrants						121,875		154,687		139,688
Price per share						$ 9.5968		$ 15.99		$ 31.99
Sales Agreement [Member] \| Common Warrants Series E [Member]
Number of shares for common warrants						458,334
Exercise price						$ 10.56
Warrants term						5 years 6 months
Sales Agreement [Member] \| Common Warrants [Member]
Number of shares for common warrants										218,750
Price per share								$ 16.00		$ 32.00
Exercise price										$ 32.00
Sales Agreement [Member] \| Common Warrants Series A [Member]
Number of shares for common warrants								281,250
Exercise price								$ 16.00
Warrants term								5 years
Sales Agreement [Member] \| Common Warrants Series B [Member]
Number of shares for common warrants								281,250
Exercise price								$ 16.00
Warrants term								1 year
Purchase Agreement with Lincoln Park 2022 [Member]
Number of shares issued																0				3,000
Net proceeds																$ 0				$ 400,000
Purchase Agreement with Lincoln Park 2022 [Member] \| Lincoln Park Capital Fund, LLC [Member]
Number of shares issued											3,125
Common stock, to be issued											$ 50,000,000
Value of shares issued											$ 1,000,000
Common Stock [Member]
Number of shares issued														3,393,600	4,369,807		13,766	16,089
Value of shares issued														$ 3,000	$ 4,000
Common Stock [Member] \| Purchase Agreement [Member]
Number of shares issued		3,393,600
Price per share		$ 0.57
Common Stock, Pre-funded Warrants and Equity Classified Common Warrants D [Member] \| Purchase Agreement [Member]
Stock offering expenses							1,400,000
Proceeds from equity offerings							$ 7,500,000